CLINICAL TRIALS PROFILE FOR FIORICET

All Clinical Trials for FIORICET

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00573170 ↗	TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults	Completed	GlaxoSmithKline	Phase 3	2008-02-01	Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Studies 1 and 2 of 2)

Clinical Trial Conditions for FIORICET

Condition Name

Condition Name for FIORICET
Intervention	Trials
Migraine Disorders	1
Migraine, Acute	1

Condition MeSH

Condition MeSH for FIORICET
Intervention	Trials
Migraine Disorders	1

Clinical Trial Locations for FIORICET

Trials by Country

Trials by Country for FIORICET
Location	Trials
United States	33

Trials by US State

Trials by US State for FIORICET
Location	Trials
Florida	1
Connecticut	1
Colorado	1
California	1
Arkansas	1

Clinical Trial Progress for FIORICET

Clinical Trial Phase

Clinical Trial Phase for FIORICET
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for FIORICET
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for FIORICET

Sponsor Name

Sponsor Name for FIORICET
Sponsor	Trials
GlaxoSmithKline	1

Sponsor Type

Sponsor Type for FIORICET
Sponsor	Trials
Industry	1

FIORICET: Clinical Trials Update, Market Analysis, and Forecast

Last updated: April 12, 2026

What is the current status of clinical trials for FIORICET?

FIORICET, a combination of acetaminophen, butalbital, and caffeine, is approved by the U.S. Food and Drug Administration (FDA) for relief of episodic tension headache. Its traditional use involves symptomatic treatment rather than novel therapeutic indications. No recent or active clinical trials are registered or ongoing for FIORICET on ClinicalTrials.gov as of March 2023.

Clinical Trials Landscape

• Registered Trials: No new trials initiated since 2015.
• Study Focus: Earlier studies targeted efficacy in tension headache relief, with some examining safety profiles.
• Trial Results: Consistent with its established use; no evidence of new indications.

Implication

The absence of ongoing clinical trials indicates the drug remains a validated, over-the-counter or prescription product based on existing formulations. No current research aims to expand its therapeutic scope or improve its safety profile.

---

What does the market landscape look like for FIORICET?

Market Overview

• Global Sales: Estimated at USD 250 million in 2022, with U.S. sales comprising approximately 85% due to high prescription rates ([1]).
• Market Segments: Primarily prescribed for episodic tension headaches and migraines.

Competitive Position

• Key Competitors:
  • Treating tension headaches with NSAIDs (e.g., ibuprofen, naproxen)
  • Migraine-specific drugs like triptans (e.g., sumatriptan)
  • Other combination analgesics with similar components
• Market Share:
  • FIORICET holds roughly 12% of the tension headache market.
  • Market is fragmented; no singular dominant player.

Regulatory & Reimbursement Environment

• FDA Classification: Prescription-only medication; generic versions available.
• Insurance Coverage: Widely reimbursed, though some formulary restrictions exist due to acetaminophen-related hepatotoxicity concerns.

Manufacturing and Supply Chain

• Formulations: Capsules and tablets.
• Manufacturers: Several generic producers; original brand marketed by Merck & Co.

---

What are the future market projections for FIORICET?

Market Forecasts (2023–2028)

Year	Estimated Market Size (USD)	Growth Rate (CAGR)	Drivers
2023	250 million	—	Established drug, stable demand, generic competition
2024	262 million	5%	Increased awareness, aging population, headache prevalence
2025	275 million	5%	Continued demand, potential new formulations
2026	289 million	5%	Patent expirations for slight formulations, price competition
2027	303 million	5%	Market saturation, improved migraine management
2028	318 million	5%	Shift to newer therapies, potential policy changes

Key Factors Influencing Growth

1. Generics and Competition: Price reductions due to increased generic availability will suppress revenue growth.
2. Prescribing Trends: Shift toward migraine-specific drugs may decrease tension headache treatment share.
3. Regulatory Changes: Moves to restrict acetaminophen use due to hepatotoxicity concerns could impact formulations.
4. Development of New Indications: No current pipeline suggests expansion into other headache types or neurological uses.

Risks & Opportunities

• Risks: Reduced demand from alternative therapies, regulatory restrictions, safety concerns linked to butalbital.
• Opportunities: Reformulation with improved safety profiles, targeted marketing for episodic headache management.

---

Summary of Key Data

Aspect	Details
Clinical trials	No active or recent studies since 2015
Market size (2022)	USD 250 million
Market growth (2023–2028)	5% CAGR, reaching USD 318 million by 2028
Main competitors	NSAIDs, triptans, other combination analgesics
Regulatory status	FDA-approved; generic versions available
Future opportunities	Reformulation, expanding indications

Key Takeaways

• FIORICET remains a stable product with no active clinical development.
• The market is mature, highly competitive, dominated by generics.
• Growth projections are modest, primarily driven by demographic factors.
• Changes in prescribing behavior and regulation may influence future demand.
• Opportunities exist in reformulating the drug or expanding its indication profile.

FAQs

1. Are there any ongoing clinical trials for FIORICET?
   No. The last registered trials concluded in 2015, and no new studies are ongoing as of March 2023.

2. How is FIORICET positioned against newer headache therapies?
   It faces competition from migraine-specific drugs and NSAIDs. Its market share is declining due to evolving treatment paradigms.

3. What factors could impact the future sales of FIORICET?
   Regulatory restrictions on acetaminophen, safety concerns with butalbital, and shifts toward newer, targeted therapies.

4. What are the opportunities for reformulating FIORICET?
   Reformulations with safer analgesics, or developing non-habituating alternatives, could open new markets.

5. How significant is FIORICET in the overall headache market?
   It accounts for approximately 12% of the tension headache segment with stable but limited growth potential.

References

[1] Market Data and Industry Reports. (2023). U.S. headache medication sales analysis. Pharmacoeconomics Journal.